NASDAQ:FMI - Foundation Medicine Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $136.95 +0.05 (+0.04 %) (As of 07/22/2018 04:00 PM ET)Previous Close$136.95Today's Range$136.75 - $136.9552-Week Range$31.70 - $137.20Volume894,530 shsAverage Volume638,722 shsMarket Capitalization$5.09 billionP/E Ratio-30.43Dividend YieldN/ABeta-0.08 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Foundation Medicine, Inc. provides various molecular information products in the United States. The company's molecular information platform includes proprietary methods and algorithms to analyze specimens across various types of cancer, as well as for incorporating that information into clinical care; and offers genomic insights about each patient's individual cancer, enabling physicians to optimize treatments in clinical practice and biopharmaceutical companies to develop targeted therapies and immunotherapies. It provides clinical products, such as FoundationOne for solid tumors; FoundationOne Heme for blood-based cancers, or hematologic malignancies, including leukemia, lymphoma, and sarcomas; Foundation Assay for Circulating Tumor; FoundationFocus CDxBRCA, a diagnostic assay to aid in identifying women with ovarian cancer; and FoundationOne CDx, a diagnostic assay for solid tumors. The company also offers FoundationCORE, a knowledgebase to publish scientific and medical advances, and foster relationships throughout the oncology community. In addition, it has strategic collaboration agreements with F. Hoffmann-La Roche Ltd.; and Genentech, Inc. Foundation Medicine, Inc. has a collaboration with The European Organisation for Research and Treatment of Cancer to advance precision medicine using comprehensive genomic profiling to facilitate clinical trial enrollment. It also has a three-party collaboration agreement with F. Hoffmann-La Roche Ltd and DIAN Diagnostics Group, Co., Ltd. to integrate the company's comprehensive genomic profiling assays into clinical patient care in mainland China. The company was founded in 2009 and is headquartered in Cambridge, Massachusetts. Foundation Medicine, Inc. is a subsidiary of Roche Holdings, Inc. Receive FMI News and Ratings via Email Sign-up to receive the latest news and ratings for FMI and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical SymbolNASDAQ:FMI CUSIPN/A Webwww.foundationmedicine.com Phone617-418-2200 Debt Debt-to-Equity Ratio4.76 Current Ratio2.27 Quick Ratio1.98 Price-To-Earnings Trailing P/E Ratio-30.43 Forward P/E Ratio-31.70 P/E GrowthN/A Sales & Book Value Annual Sales$152.90 million Price / Sales33.27 Cash FlowN/A Price / CashN/A Book Value$0.87 per share Price / Book157.41 Profitability EPS (Most Recent Fiscal Year)($4.50) Net Income$-161,460,000.00 Net Margins-84.96% Return on Equity-299.63% Return on Assets-94.81% Miscellaneous Employees662 Outstanding Shares37,140,000Market Cap$5,085.91 Foundation Medicine (NASDAQ:FMI) Frequently Asked Questions What is Foundation Medicine's stock symbol? Foundation Medicine trades on the NASDAQ under the ticker symbol "FMI." How were Foundation Medicine's earnings last quarter? Foundation Medicine Inc (NASDAQ:FMI) released its quarterly earnings data on Wednesday, May, 2nd. The company reported ($1.02) earnings per share for the quarter, topping the consensus estimate of ($1.10) by $0.08. The business earned $52.84 million during the quarter, compared to analysts' expectations of $44.99 million. Foundation Medicine had a negative return on equity of 299.63% and a negative net margin of 84.96%. The business's revenue was up 100.7% on a year-over-year basis. During the same quarter last year, the business posted ($1.31) EPS. View Foundation Medicine's Earnings History. When is Foundation Medicine's next earnings date? Foundation Medicine is scheduled to release their next quarterly earnings announcement on Monday, July, 30th 2018. View Earnings Estimates for Foundation Medicine. What price target have analysts set for FMI? 4 Wall Street analysts have issued 1 year target prices for Foundation Medicine's shares. Their predictions range from $73.00 to $90.00. On average, they anticipate Foundation Medicine's stock price to reach $81.00 in the next year. This suggests that the stock has a possible downside of 40.9%. View Analyst Ratings for Foundation Medicine. What is the consensus analysts' recommendation for Foundation Medicine? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Foundation Medicine in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." Are investors shorting Foundation Medicine? Foundation Medicine saw a decline in short interest in June. As of June 29th, there was short interest totalling 1,387,249 shares, a decline of 40.9% from the June 15th total of 2,349,217 shares. Based on an average trading volume of 1,716,151 shares, the short-interest ratio is presently 0.8 days. Currently, 9.2% of the company's shares are sold short. View Foundation Medicine's Current Options Chain. Who are some of Foundation Medicine's key competitors? Some companies that are related to Foundation Medicine include Laboratory Corp. of America (LH), Quest Diagnostics (DGX), ELEKTA AB/ADR (EKTAY), Genomic Health (GHDX), Natera (NTRA), RadNet (RDNT), InVitae (NVTA), CareDx (CDNA), Veracyte (VCYT), Celcuity (CELC), Enzo Biochem (ENZ), Miragen Therapeutics (MGEN), PotNetwork (POTN), Psychemedics (PMD) and Fulgent Genetics (FLGT). Who are Foundation Medicine's key executives? Foundation Medicine's management team includes the folowing people: Mr. Troy Cox, CEO, Pres & Director (Age 54)Mr. Michael Doherty, Head of Product Devel. (Age 59)Mr. Jason Ryan, Chief Financial Officer (Age 44)Mr. Konstantin Fiedler, Chief Operating Officer (Age 52)Mr. Tom Godden, Chief Information Officer Has Foundation Medicine been receiving favorable news coverage? Media stories about FMI stock have trended somewhat positive on Sunday, according to Accern Sentiment Analysis. The research group ranks the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Foundation Medicine earned a media sentiment score of 0.06 on Accern's scale. They also gave media coverage about the company an impact score of 47.27 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days. Who are Foundation Medicine's major shareholders? Foundation Medicine's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (1.09%), Peregrine Capital Management LLC (0.59%), Boston Advisors LLC (0.34%), Tokio Marine Asset Management Co. Ltd. (0.05%), Fred Alger Management Inc. (0.02%) and Creative Planning (0.01%). Company insiders that own Foundation Medicine stock include David Daly, Evan/ Fa Jones, Jason Ryan, Konstantin Fiedler, Krishna Yeshwant, Michael J Doherty, Michael J Pellini, Robert W Hesslein, Steven J Kafka, Troy Cox and Vincent A Miller. View Institutional Ownership Trends for Foundation Medicine. Which institutional investors are selling Foundation Medicine stock? FMI stock was sold by a variety of institutional investors in the last quarter, including Boston Advisors LLC, Prentiss Smith & Co. Inc., Peregrine Capital Management LLC and Creative Planning. Company insiders that have sold Foundation Medicine company stock in the last year include David Daly, Evan/ Fa Jones, Jason Ryan, Konstantin Fiedler, Krishna Yeshwant, Michael J Doherty, Michael J Pellini, Robert W Hesslein, Steven J Kafka, Troy Cox and Vincent A Miller. View Insider Buying and Selling for Foundation Medicine. Which institutional investors are buying Foundation Medicine stock? FMI stock was acquired by a variety of institutional investors in the last quarter, including Tokio Marine Asset Management Co. Ltd., Baillie Gifford & Co., Amalgamated Bank, Xact Kapitalforvaltning AB and Fred Alger Management Inc.. View Insider Buying and Selling for Foundation Medicine. How do I buy shares of Foundation Medicine? Shares of FMI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Foundation Medicine's stock price today? One share of FMI stock can currently be purchased for approximately $136.95. How big of a company is Foundation Medicine? Foundation Medicine has a market capitalization of $5.09 billion and generates $152.90 million in revenue each year. The company earns $-161,460,000.00 in net income (profit) each year or ($4.50) on an earnings per share basis. Foundation Medicine employs 662 workers across the globe. How can I contact Foundation Medicine? Foundation Medicine's mailing address is 150 Second Street, Cambridge MA, 02141. The company can be reached via phone at 617-418-2200 or via email at [email protected] MarketBeat Community Rating for Foundation Medicine (NASDAQ FMI)Community Ranking: 1.6 out of 5 ()Outperform Votes: 148 (Vote Outperform)Underperform Votes: 311 (Vote Underperform)Total Votes: 459MarketBeat's community ratings are surveys of what our community members think about Foundation Medicine and other stocks. Vote "Outperform" if you believe FMI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FMI will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/22/2018 by MarketBeat.com StaffFeatured Article: What does earnings per share mean?